RESTATEMENT OF FINANCIAL STATEMENTS (Details 1) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) attributable to Manhattan Scientifics, Inc.		$ (1,371,000)	$ 9,046,000	$ (4,199,000)	$ 6,920,000
Adjustments to reconcile net income/(loss) to net cash provided by (used in) operating activities:
Depreciation and amortization				365,000	428,000
Gain on FV of Investments		973,000	(203,000)	3,373,000	(203,000)
Gain on deconsolidation of subsidiary			(7,940,000)		(7,940,000)
Changes in:
Accounts receivable					30,000
Prepaid expenses				3,000	(3,000)
Accounts payable and accrued expenses				69,000	300,000
Net cash provided by/(used in) operating activities				(139,000)	(469,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Net cash (used in)/provided by financing activities
NET INCREASE IN CASH AND CASH EQUIVALENTS				(139,000)	(469,000)
Cash and cash equivalents, beginning of year				269,000	1,068,000
CASH AND CASH EQUIVALENTS, END OF YEAR		$ 130,000	599,000	130,000	599,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid
(Original Amount)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) attributable to Manhattan Scientifics, Inc.			2,117,000		463,000
Adjustments to reconcile net income/(loss) to net cash provided by (used in) operating activities:
Stock options issued/vested for services
Depreciation and amortization					428,000
Treasury stock cancelled and returned to authorized
(Gain)/Loss on forgiveness of debt			6,739,000		6,739,000
Gain on FV of Investments
Gain on deconsolidation of subsidiary
Changes in:
Accounts receivable					30,000
Prepaid expenses					(3,000)
Accounts payable and accrued expenses					(40,000)
Accrued interest and expenses, related parties					(1,000)
Net cash provided by/(used in) operating activities					7,616,000
CASH FLOWS FROM INVESTING ACTIVITIES:
Adjustment for noncontrolling interest					(8,758,000)
Reduction of assets due to deconsolidation of noncontrolling interest					696,000
Purchase of fixed assets					(23,000)
Net cash used in investing activities					(8,085,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from note payable - related party
Payments on notes payable other
Proceeds from issuance of common stock
Repurchase of common stock for treasury
Net cash (used in)/provided by financing activities
NET INCREASE IN CASH AND CASH EQUIVALENTS					(469,000)
Cash and cash equivalents, beginning of year					1,068,000
CASH AND CASH EQUIVALENTS, END OF YEAR			599,000		599,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid
SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES:
Conversion of debt to preferred stock by shareholder
Loss on forgiveness of debt
Gain in change in accounting treatment
(Adjustments)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) attributable to Manhattan Scientifics, Inc.					6,457,000
Adjustments to reconcile net income/(loss) to net cash provided by (used in) operating activities:
Stock options issued/vested for services
Depreciation and amortization
Treasury stock cancelled and returned to authorized
(Gain)/Loss on forgiveness of debt	[1]		(6,739,000)		(6,739,000)
Gain on FV of Investments	[1]		(203,000)		(203,000)
Gain on deconsolidation of subsidiary	[1]		(7,940,000)		(7,940,000)
Changes in:
Accounts receivable
Prepaid expenses
Accounts payable and accrued expenses	[1]				340,000
Accrued interest and expenses, related parties
CASH FLOWS FROM INVESTING ACTIVITIES:
Adjustment for noncontrolling interest	[1]				8,758,000
Reduction of assets due to deconsolidation of noncontrolling interest	[1]				(696,000)
Purchase of fixed assets	[1]				23,000
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from note payable - related party
Payments on notes payable other
Proceeds from issuance of common stock
Repurchase of common stock for treasury
(Corrected Amount)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) attributable to Manhattan Scientifics, Inc.			9,046,000		6,920,000
Adjustments to reconcile net income/(loss) to net cash provided by (used in) operating activities:
Stock options issued/vested for services
Depreciation and amortization					428,000
Treasury stock cancelled and returned to authorized
(Gain)/Loss on forgiveness of debt
Gain on FV of Investments			(203,000)		(203,000)
Gain on deconsolidation of subsidiary			(7,940,000)		(7,940,000)
Changes in:
Accounts receivable					30,000
Prepaid expenses					(3,000)
Accounts payable and accrued expenses					300,000
Accrued interest and expenses, related parties					(1,000)
Net cash provided by/(used in) operating activities					(469,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Adjustment for noncontrolling interest
Reduction of assets due to deconsolidation of noncontrolling interest
Purchase of fixed assets
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from note payable - related party
Payments on notes payable other
Proceeds from issuance of common stock
Repurchase of common stock for treasury
Net cash (used in)/provided by financing activities
NET INCREASE IN CASH AND CASH EQUIVALENTS					(469,000)
Cash and cash equivalents, beginning of year					1,068,000
CASH AND CASH EQUIVALENTS, END OF YEAR			$ 599,000		599,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid
SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES:
Conversion of debt to preferred stock by shareholder
Loss on forgiveness of debt
Gain in change in accounting treatment					$ (7,940,000)

[1] Deconsolidation of Imagion Biosystems, Inc. and recording investment at fair value